FLGT trades 10.7% above Wall Street's consensus target of $19.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes FLGT achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Fulgent Genetics, Inc. (FLGT) has a Wall Street consensus price target of $19.00, based on estimates from 9 covering analysts. With the stock currently trading at $21.27, this represents a potential downside of -10.7%. The company has a market capitalization of $604M.
Analyst price targets range from a low of $19.00 to a high of $19.00, representing a 0% spread in expectations. The median target of $19.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, FLGT trades at a trailing P/E of -10.8x. Analysts expect EPS to grow +24.7% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NTRANatera, Inc. | $56.0B | $390.79 | $335.07 | -14.3% | Buy | — | 28 |
 EXASExact Sciences Corporation | $20.0B | $104.91 | $92.95 | -11.4% | Buy | 582.8x | 41 |
 PACBPacific Biosciences of California, Inc. | $438M | $1.41 | $1.18 | -16.3% | Buy | — | 18 |
 LHLabcorp Holdings Inc. | $24.9B | $303.98 | $337.29 | +11.0% | Buy | 16.6x | 35 |
 DGXQuest Diagnostics Incorporated | $25.7B | $233.00 | $246.67 | +5.9% | Hold | 20.8x | 34 |
 MYRGMYR Group Inc. | $4.6B | $295.18 | $444.40 | +50.6% | Hold | 24.2x | 21 |
 CDNACareDx, Inc | $2.8B | $54.31 | $58.75 | +8.2% | Buy | 45.1x | 13 |
 PGNYProgyny, Inc. | $2.0B | $25.83 | $35.50 | +37.4% | Buy | 20.1x | 20 |
 CSTLCastle Biosciences, Inc. | $1.1B | $34.88 | $39.00 | +11.8% | Buy | — | 11 |
 ILMNIllumina, Inc. | $38.6B | $255.38 | $210.67 | -17.5% | Buy | 47.7x | 50 |
Quick answers to the most common questions about buying FLGT stock.
FLGT's consensus price target is $19, -10.7% below the current price of $21.27. The 9 analysts tracking FLGT see downside risk at present valuations.
FLGT has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $19 implies -10.7% downside from current levels.
FLGT's current price is $21.27 with a consensus target of $19 (-10.7% implied move). Analyst estimates suggest the stock is overvalued at current levels.
The most bullish Wall Street analyst has a price target of $19 for FLGT, while the most conservative target is $19. The consensus of $19 represents the median expectation. These targets typically reflect 12-month expectations.
FLGT is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month FLGT stock forecast based on 9 Wall Street analysts shows a consensus price target of $19, with estimates ranging from $19 (bear case) to $19 (bull case). The median consensus rating is "Buy".
Analysts are cautious on FLGT, with 0 Sell ratings and a price target of $19 (-10.7% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
FLGT analyst price targets range from $19 to $19, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $19 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.